New drug KR25102 tested in healthy people for first time
NCT ID NCT07618156
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial will test the safety and tolerability of a new drug called KR25102 in 83 healthy adults in China. Participants will receive either a single dose or multiple daily doses of the drug or a placebo. The main goal is to check for side effects and understand how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KR25102
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third Xiangya Hospital, Central South University
Changsha, Hunan, 410006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsing light on the scalp boost brain performance?
- Can heavy water reveal how the liver makes fat?
- Which bridge exercise fires up your muscles most? a study investigates
- A new molecule enters human testing: can ZE66-0205 prove safe?
- Reading DNA clues: a blood test that could sniff out lung cancer
- Blood flow restriction may change how hamstrings use oxygen during exercise